KalVista Pharmaceuticals Inc. (NASDAQ: KALV) announced interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY (sebetralstat) for treating hereditary angioedema ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA